CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, announced its participation in the upcoming H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright Global Investment Conference. CEO Rachel Leheny, Ph.D. will present on September 8, 2025, at 3:30 p.m. ET.
The presentation will be available via live webcast in the "IR Events and Presentations" section of CalciMedica's website, with a replay accessible for 90 days following the event.
Details
News Market Reaction – CALC
On Sep 2, the day this news came out, CALC closed 14.81% above the previous close. That session’s volume was 12.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated respiratory failure. For more information, please visit www.calcimedica.com.
Contact Information
Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302542326.html
SOURCE CalciMedica, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.